NASDAQ:ABOS - Get Free Report ) will be announcing its earnings results before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link .
Get Acumen Pharmaceuticals alerts:
Sign Up
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report ) last issued its earnings results on Tuesday, March 26th. The company reported ($0.29) EPS for the quarter, meeting the consensus estimate of ($0.29). On average, analysts expect Acumen Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Acumen Pharmaceuticals Stock Up 1.2 % Shares of ABOS stock traded up $0.04 during mid-day trading on Wednesday, hitting $3.40. The company's stock had a trading volume of 149,899 shares, compared to its average volume of 355,901. The stock has a market cap of $204.27 million, a price-to-earnings ratio of -3.13 and a beta of 0.19. The company has a debt-to-equity ratio of 0.11, a quick ratio of 19.01 and a current ratio of 19.01. Acumen Pharmaceuticals has a 52-week low of $1.81 and a 52-week high of $11.31. The business has a 50-day moving average price of $3.84 and a 200 day moving average price of $3.33.
Analyst Upgrades and Downgrades Separately, HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Wednesday, March 27th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $12.25.
Check Out Our Latest Report on ABOS
About Acumen Pharmaceuticals (
Get Free Report )
Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Further Reading
Before you consider Acumen Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.
While Acumen Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
